Abstract
Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 897-901 |
| Number of pages | 5 |
| Journal | Mayo Clinic Proceedings |
| Volume | 75 |
| Issue number | 9 |
| State | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Thalidomide in the treatment of relapsed multiple myeloma. / Rajkumar, S Vincent; Fonseca, Rafael; Dispenzieri, Angela; Lacy, Martha; Lust, John A.; Witzig, Thomas Elmer; Kyle, Robert A.; Gertz, Morie; Greipp, Philip R.
In: Mayo Clinic Proceedings, Vol. 75, No. 9, 2000, p. 897-901.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Thalidomide in the treatment of relapsed multiple myeloma
AU - Rajkumar, S Vincent
AU - Fonseca, Rafael
AU - Dispenzieri, Angela
AU - Lacy, Martha
AU - Lust, John A.
AU - Witzig, Thomas Elmer
AU - Kyle, Robert A.
AU - Gertz, Morie
AU - Greipp, Philip R.
PY - 2000
Y1 - 2000
N2 - Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.
AB - Objective: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods: We studied 16 patients (median age, 64 years), who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. Results: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. Conclusion: Thalidomide is an active agent in the treatment of patients with advanced myeloma.
UR - http://www.scopus.com/inward/record.url?scp=0033815863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033815863&partnerID=8YFLogxK
M3 - Article
C2 - 10994824
AN - SCOPUS:0033815863
VL - 75
SP - 897
EP - 901
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 9
ER -